Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets.
Minyoung JangSteven R A SimoensTaeksang KwonPublished in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy (2020)
This budget impact analysis emphasised that increased use of intravenous rituximab and trastuzumab biosimilars may result in cost savings from the payer's perspective across the EU-5 countries.